Cancer Research

Multiple myeloma
#Cancer research #Myeloma #National Institute for Health and Care Excellence (NICE) #UK

NICE recommends triplet regimen for relapsed multiple myeloma

NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy.  Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More

#Cancer Research #News #Regulatory #Trending News

MRI showing glioblastoma
#Brain #Cancer research #Drug repurposing #Neuroscience #Oncology

FDA-approved drug sensitises brain cancer cells to radiotherapy

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.  Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.  GBM is a… Read More

#Cancer Research #News

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Bacteria
#Bacteria #Cancer research #everImmune #Oncology #Phase I trial

Oncobiotic cancer drug could be a step forward for science

The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients.  The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. … Read More

#Cancer Research #News

#Avacta #Cancer research #Chemotherapy #Oncology #Phase I trial #Precision medicine

Early trial data confirms drug’s tumour targeting potential

Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial.   Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More

#Cancer Research #Editor's Choice #News

#Autoimmune disease #Cancer research #Clinical trial #Fibrosis #Immunotherapy #Oncology

First-line clinical trial marks a turning point in drug development 

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital.  The trial   This Phase IIb clinical trial will focus on first-line… Read More

#Cancer Research #News

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

Research lab
#Cancer research #circular RNAs #Collaboration #Esperovax #Ginkgo Bioworks #High throughput screening #Oncology #Partnership #RNA

Alliance to develop circular RNA-based therapeutics

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.   Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.  CircRNAs represent an… Read More

#Cancer Research #News

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

Uveal melanoma
#Cancer research #FDA #iOnctura #Ophthalmology #Orphan drugs #United States

FDA grants orphan drug status for uveal melanoma drug

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma.  Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More

#Cancer Research #News #Regulatory

Cancer cells
#Brain disease #Cancer research #Cell and gene therapy #CRISPR #CRISPR-Cas9 #Gene editing #Mouse models #Neuroscience #Oncology

Scientists turn cancer cells into anticancer agents

Harvard investigators have developed a new cell therapy approach to eliminate established tumours and induce long-term immunity.   In this early research, Khalid Shah, Professor of Neurosurgery at Harvard Medical School and Brigham and Women’s Hospital, and colleagues tested the vaccine in an advanced mouse model of brain… Read More

#Cancer Research #News #Trending News

Cancer research
#Cancer immunotherapy #Cancer research #Funding #Immunotherapy #Investment #ISA Pharmaceuticals #Oncology #Ophthalmology #Synthetic biology

$5 million to fund trial of therapy for uveal melanoma

Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA Pharmaceuticals’ PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.  Cancer Focus Fund was established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and… Read More

#Business & Investment #Cancer Research #News

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer drug targets #Cancer research #Collaboration #Oncology #Partnership

AI-powered cancer simulations enable drug targeting

Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases.   The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.   CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More

#Business & Investment #Cancer Research #News

Pancreatic cancer
#Antibodies #Cancer immunotherapy #Cancer research #Immunotherapy #Oncology #Pancreatic cancer #Preclinical investigations

Triple immunotherapy eliminates pancreatic tumours

A novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, has significantly improved anti-tumour responses in preclinical models of pancreatic cancer.  In the study, published in Nature Cancer, researchers at The University of Texas MD Anderson Cancer Center… Read More

#Cancer Research #Editor's Choice #News

Myeloma cells
#Antibody #Cancer research #Europe #European Medicines Agency #Janssen #Marketing approval authorisation #Myeloma #T-Cells

Janssen seeks European approval for multiple myeloma drug

Janssen has submitted a marketing authorisation application (MAA) seeking approval of talquetamab in Europe for the treatment of patients with relapsed or refractory multiple myeloma (RRMM).   Talquetamab is an investigational, off-the-shelf, bispecific T-cell engager antibody targeting both GPRC5D, a novel drug target that is on some normal… Read More

#Cancer Research #News